

---

**Product Data Sheet**

---

Product Name: Kanosamine (hydrochloride)

Cat. No.: GC14432

**Chemical Properties**

Cas. No. 57649-10-2

Chemical Name 3-amino-3-deoxy-D-glucose, monohydrochloride

SMILES O=C([H])[C@H](O)[C@@H](N)[C@H](O)[C@H](O)CO.ClFormula  $C_6H_{13}NO_5 \cdot HCl$ 

M.Wt 215.6

Solubility  $\leq 5$ mg/ml in ethanol; 25mg/ml in DMSO; 25mg/ml in dimethyl formamide

Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure **Protocol****Cell experiment:**

MICs are determined by a serial dilution microtiter plates method in Yeast Nitrogen Base medium containing 1% glucose or glycerol as a carbon source. Wells containing serially diluted kanosamine and control wells are inoculated with 10<sup>5</sup> cells /mL of an overnight culture of fungal cells and incubated for 24 h at 30°C. MIC is defined as the lowest antifungal agent concentration preventing visible growth. Alternatively, MICs are determined in RPMI 1640 medium buffered with 3-[N-morpholino]propanesulphonic acid (MOPS) to pH 7, under conditions recommended by NCCLS. In all cases, reproducible sharp end points are obtained and trailing effects are not observed[1].

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

### References:

[1]. Milner JL, et al. Production of kanosamine by *Bacillus cereus* UW85. *Appl Environ Microbiol.* 1996 Aug;62(8):3061-5.

[2]. Janiak AM, et al. Mechanism of antifungal action of kanosamine. *Med Mycol.* 2001 Oct;39(5):401-8.

### Background

Kanosamine is the antibiotic produced by *Bacillus cereus* UW85. Kanosamine showed highly inhibitory effects to the growth of plant-pathogenic oomycetes and moderately inhibitory effects to certain fungi and inhibited few bacterial species tested. Kanosamine accumulation in *B. cereus* UW85 culture supernatants was enhanced by the addition of ferric iron and suppressed by addition of phosphate to rich medium. Kanosamine accumulation was also enhanced more than 300% by the addition of alfalfa seedling exudate to minimal medium [1].

Kanosamine was also produced by a *Streptomyces* SP [2]. Kanosamine inhibited cell wall synthesis in plant-pathogenic oomycetes with MIC value of 25 µg/ml for *P. medicaginis* M2913 and certain fungi as well as some bacterial species with MIC value of 400 µg/ml

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

for *S. aureus* [1,2]. It has been explored as an alternative and/or supplement to synthetic pesticides and genetic resistance of crop plants for the management of plant disease [1,2].

The antibiotic kanosamine inhibited the growth of many human pathogenic fungi. Kanosamine was transported into cells by the glucose transport system and subsequently phosphorylated to generate kanosamine-6-phosphate. The product was an inhibitor of the enzyme glucosamine-6-phosphate synthase. The Inhibitory effect was competitive to one of the substrates, D-fructose-6-phosphate, with  $K_i$  value of 5.9 mM. The action of kanosamine on *C. albicans* cells lead to profound morphological changes, inhibition of septum formation and cell agglutination [3].

### References:

- [1] Milner J L, Silo-Suh L, Lee J C, et al. Production of kanosamine by *Bacillus cereus* UW85[J]. *Applied and Environmental Microbiology*, 1996, 62(8): 3061-3065.
- [2] Dolak L A, Castle T M, Dietz A, et al. 3-Amino-3-deoxyglucose produced by a *Streptomyces* SP[J]. *The Journal of antibiotics*, 1980, 33(8): 900-901.
- [3] Janiak A M, Milewski S. Mechanism of antifungal action of kanosamine[J]. *Medical mycology*, 2001, 39(5): 401-408.

**Caution: Product has not been fully validated for medical applications. For research use only.**

**Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com**

**Address: 10292 Central Ave. #205, Montclair, CA, USA**